學歷
- 高雄醫學院醫學系
- 台灣大學預防醫學研究所碩士
- 台灣大學流行病學與預防醫學研究所博士
經歷
- 國泰綜合醫院家庭醫學科住院醫師
論文及學術著作
- Lee, Y. C., Wu, L. C., Wu, V. C., Chang, C. H. (2025)
Comparative Effectiveness of Glucagon-Like Peptide-1 Receptor Agonists and Sodium/Glucose Cotransporter 2 Inhibitors in Preventing Chronic Kidney Failure and Mortality in Patients With Type 2 Diabetes and CKD.
American journal of kidney diseases : the official journal of the National Kidney Foundation, 86(3), 301–313.e1. - T.J. Chang, Y.C. Lee*, L.C. Wu, C.H. Chang
Albuminuria-based stratification of end-stage kidney disease progression and mortality with sodium-glucose cotransporter 2 inhibitors (SGLT2i): A retrospective cohort study in type 2 diabetes and chronic kidney disease
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, October 2024 (IF 2023=2.9) - Y.C. Lee, Y.H. Dong, W.S. Yang, L.C. Wu, J.W. Lin*, C.H. Chang*
Risk of major adverse limb events in patients with type 2 diabetes mellitus receiving sodium glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists: A population-based retrospective cohort study.
Frontiers in Pharmacology, September 2022, 869804. (IF 2023=4.6; Rank Q1) - 李昀庭、李彥潔、張恬君、楊逸菊、巫麗秋、張家勳
第2型糖尿病與慢性腎病患者中鈉-葡萄糖協同轉運蛋白抑制劑對不同蛋白尿分類的腎臟預後
113年家庭醫學醫學年會，台北，台灣，14/07/2024，Poster - C.H. Chiu, Y.C. Lee, Y.C. Yang, L.C. Wu, C.H. Chang
Identifying Care Gaps in the Use of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors and county-specific quality of prescribing among Diabetes Patients with Chronic Kidney Disease: A Population Based Study in Taiwan
112年家庭醫學醫學年會, 台北, 台灣, 16/07/2023. Poster
資料更新日期:2026/5/28